Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

BACKGROUND: Patients with resistant primary focal segmental glomerulosclerosis (FSGS) are at high risk of progression to chronic kidney disease stage V. Antifibrotic agents may slow or halt this process. We present outcomes of follow-up after a Phase I trial of adalimumab and rosiglitazone, antifibr...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Peyser, Alexandra, MacHardy, Nathaniel, Tarapore, Freya, MacHardy, Jacqueline, Powell, Leslie, Gipson, Debbie S, Savin, Virginia, Pan, Cynthia, Kump, Theresa, Vento, Suzanne, Trachtman, Howard
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2010
Konular:
Research article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2823728/
https://ncbi.nlm.nih.gov/pubmed/20113498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2369-11-2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller